Hadassah

Israeli Start-up’s Algorithm Predicts Which Diabetic Patients Will Suffer Kidney Dysfunction Within One Year

Wednesday, Feb 7 2018

Dr. Itamar Raz

The Israeli start-up Medial EarlySign has created a machine-learning-based model that has proven to identify diabetic patients who are at the highest risk for experiencing renal dysfunction within one year.

The Medial EarlySign's algorithm is able to identify 25 percent more patients than the current commonly used clinical tools by analyzing dozens of factors residing in Electronic Health Records, such as laboratory test results, medication, diagnostic codes, and demographics.

"The significant size and rapid growth of digital health databases now allow the application of advanced mathematical tools that can spot patterns in diverse patient populations in order to identify high-risk patients," relates Dr. Itamar Raz, Director Emeritus of the Diabetes Unit at the Hadassah Medical Organization and head of Israel’s National Diabetes Council. "Rather than relying only on small patient samples based on known risk factors,” Dr. Raz explains, “machine learning tools can reveal the slightest correlations among these parameters and discover additional risk indicators that can lead to improved prediabetic patient risk stratification (which involves classifying people into well-defined risk groups).”

By isolating less than five percent of the 400,000 diabetic patients within the company's database of 15 million patients, the algorithm was able to identify 45 percent of patients who would progress to significant kidney damage within a year. This was before they became symptomatic.

Kidney problems are one of the most common diabetes-related complications, affecting millions of people--approximately 20-40 percent of diabetics worldwide, according to Medial EarlySign. The company’s expectation is that the numbers will continue to rise as diabetes becomes more prevalent.

Learn more about the Hadassah Medical Organization.

Comments

No comments yet.
First Name
Email
Comment
Enter this word:

Related Stories

alt_text

Wednesday, Jun 12 2019

Multinational Study Reveals Reduction in Kidney Disease Progression with Diabetes Drug

In a large multinational study that revealed the effectiveness of a medicine called dapagliflozin in reducing cardiovascular death from heart failure among high-risk diabetic patients, the first sub-analysis of renal data has also identified a 47 percent drop in decline of kidney function and renal death.

READ MORE ›
alt_text

Wednesday, Jun 5 2019

What Causes PMS? Hadassah Study Offers Answer, with Implications for Future Research

A new explanation for the mood swings, irritability, and depression, known as Premenstrual syndrome (PMS) has been suggested by a Hadassah Medical Organization study.

READ MORE ›
alt_text

Wednesday, Jun 5 2019

Hadassah Confronts the Comeback of Measles

Measles, a disease we have not seen for a long time, has come back. In the past year and a half, Israel has seen over 4,000 cases, says Prof. Allon Moses, director of the Department of Clinical Microbiology and Infectious Diseases at the Hadassah Medical Organization.

READ MORE ›
alt_text

Wednesday, May 29 2019

First Cath Lab Opens in Northern Neighborhoods of Jerusalem at Hadassah Mount Scopus

Hadassah Hospital Mount Scopus inaugurated the first advanced cardiac catheterization unit serving Jerusalem’s northern neighborhoods.

READ MORE ›

Donation Questions

donorservices@hadassah.org

(800) 928-0685

Membership Questions

membership@hadassah.org

(800) 664-5646

Missions Department

missions@hadassah.org

(800) 237-1517

Contact Us

40 Wall Street

New York, NY 10005

support@hadassah.org

More ›

Show More